Daniel Shu Wei Ting1, Wei Yan Ng2, Si Rui Ng2, Shu Pei Tan3, Ian Yew San Yeo1, Ranjana Mathur1, Choi Mun Chan2, Anna Cheng Sim Tan2, Gavin Siew Wei Tan1, Tien Yin Wong1, Chui Ming Gemmy Cheung4. 1. Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore. 2. Singapore National Eye Centre, Singapore. 3. Singapore Eye Research Institute, Singapore. 4. Singapore National Eye Centre, Singapore; Singapore Eye Research Institute, Singapore; Duke-NUS (National University of Singapore) Graduate Medical School, National University of Singapore, Singapore. Electronic address: gemmy.cheung.c.m@snec.com.sg.
Abstract
PURPOSE: To describe 12-month changes in choroidal thickness after anti-vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). DESIGN: Prospective, consecutive, noninterventional, longitudinal case series. METHODS: This study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure choroidal thickness. RESULTS: Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and received fewer anti-VEGF injections (3.9 vs 5.6, P = .02) than patients with typical AMD. Baseline subfoveal choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 μm, P < .01). Subfoveal choroidal thickness decreased significantly in both typical AMD (213.7 μm to 190.3 μm, P < .001) and PCV (240.8 μm to 213.4 μm, P < .01) eyes, but no significant change was noted in fellow unaffected eyes. Reduction in choroidal thickness was associated with elevated C-reactive protein (odds ratio [OR]: 1.4, P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness. CONCLUSIONS: A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment.
PURPOSE: To describe 12-month changes in choroidal thickness after anti-vascular endothelial growth factor (anti-VEGF) therapy for typical age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV). DESIGN: Prospective, consecutive, noninterventional, longitudinal case series. METHODS: This study included patients with typical AMD and PCV who received anti-VEGF therapy over a 12-month period. We used spectral-domain optical coherence tomography with enhanced depth imaging mode to measure choroidal thickness. RESULTS: Of the 163 patients, 77 had typical AMD and 86 had PCV. Patients with PCV were younger (67.6 vs 72.5 years, P < .01) and received fewer anti-VEGF injections (3.9 vs 5.6, P = .02) than patients with typical AMD. Baseline subfoveal choroidal thickness was not significantly different between PCV and typical AMD eyes, and was thicker in the study eye compared to fellow eye in the typical AMD group (223.1 vs 208.8 μm, P < .01). Subfoveal choroidal thickness decreased significantly in both typical AMD (213.7 μm to 190.3 μm, P < .001) and PCV (240.8 μm to 213.4 μm, P < .01) eyes, but no significant change was noted in fellow unaffected eyes. Reduction in choroidal thickness was associated with elevated C-reactive protein (odds ratio [OR]: 1.4, P = .04) and smoking (OR: 7.6, P = .03) at baseline, but not with age, refractive error, diagnosis of typical AMD or PCV, number or type of anti-VEGF injections, PDT therapy, or baseline choroidal thickness. CONCLUSIONS: A significant reduction in subfoveal choroidal thickness was noted after anti-VEGF therapy in typical AMD and PCV. Choroidal thickness changes were similar despite differences in number of anti-VEGF treatment.
Authors: Daniel Shu Wei Ting; Carol Yim-Lui Cheung; Gilbert Lim; Gavin Siew Wei Tan; Nguyen D Quang; Alfred Gan; Haslina Hamzah; Renata Garcia-Franco; Ian Yew San Yeo; Shu Yen Lee; Edmund Yick Mun Wong; Charumathi Sabanayagam; Mani Baskaran; Farah Ibrahim; Ngiap Chuan Tan; Eric A Finkelstein; Ecosse L Lamoureux; Ian Y Wong; Neil M Bressler; Sobha Sivaprasad; Rohit Varma; Jost B Jonas; Ming Guang He; Ching-Yu Cheng; Gemmy Chui Ming Cheung; Tin Aung; Wynne Hsu; Mong Li Lee; Tien Yin Wong Journal: JAMA Date: 2017-12-12 Impact factor: 56.272
Authors: Yasuo Yanagi; Aditi Mohla; Shu Yen Lee; Ranjana Mathur; Choi Mun Chan; Ian Yeo; Tien Yin Wong; Chui Ming Gemmy Cheung Journal: JAMA Ophthalmol Date: 2018-08-01 Impact factor: 7.389
Authors: Vivian S Vuong; Elad Moisseiev; David Cunefare; Sina Farsiu; Ala Moshiri; Glenn Yiu Journal: Am J Ophthalmol Date: 2016-06-23 Impact factor: 5.258
Authors: Chui Ming Gemmy Cheung; Won Ki Lee; Hideki Koizumi; Kunal Dansingani; Timothy Y Y Lai; K Bailey Freund Journal: Eye (Lond) Date: 2018-07-11 Impact factor: 3.775
Authors: Gui-Shuang Ying; Maureen G Maguire; Wei Pan; Juan E Grunwald; Ebenezer Daniel; Glenn J Jaffe; Cynthia A Toth; Stephanie A Hagstrom; Daniel F Martin Journal: Ophthalmol Retina Date: 2018-06